Avalyn Pharma Inc. (NASDAQ:AVLN) Short Interest Update

Avalyn Pharma Inc. (NASDAQ:AVLN) was the recipient of a significant increase in short interest in May. As of May 15th, there was short interest totaling 562,374 shares, an increase of ∞ from the April 30th total of 0 shares. Based on an average daily trading volume, of 416,629 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.3% of the company’s stock are sold short.

Avalyn Pharma Stock Down 7.7%

AVLN stock traded down $2.23 during midday trading on Monday, reaching $26.55. 81,948 shares of the company were exchanged, compared to its average volume of 347,826. Avalyn Pharma has a one year low of $25.05 and a one year high of $32.22.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on AVLN shares. Zacks Research upgraded shares of Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th. Wall Street Zen upgraded shares of Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Evercore started coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 target price on the stock. Guggenheim started coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They set a “buy” rating and a $80.00 target price on the stock. Finally, Morgan Stanley started coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Avalyn Pharma has a consensus rating of “Buy” and a consensus price target of $59.00.

Insider Buying and Selling

In other Avalyn Pharma news, Director Jill Carroll acquired 277,778 shares of the stock in a transaction dated Friday, May 1st. The shares were bought at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the acquisition, the director directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This trade represents a 14.55% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the stock in a transaction dated Friday, May 1st. The stock was acquired at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the insider directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. The trade was a 34.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.